Aequus Pharmaceuticals welcomes Stu Fowler as strategic commercial advisor; Ian Ball transitions into Medicom role

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) is welcoming seasoned ophthalmology executive Stu Fowler, who is coming on board as a strategic commercial advisor with a seat on the firm’s board. 

Fowler recently serves as the general manager of Alcon in Canada and was formerly president of Allergan Canada. Both firms are among the largest ophthalmology companies in the country. 

The Vancouver-based firm also announced that its chief commercial officer Ian Ball is transitioning into a senior role with the firm’s UK partner Medicom Healthcare.

READ: Aequus Pharmaceuticals hails further boost to its growing Sandoz tacrolimus revenues across Canada

“We are excited to welcome Stu to the team and look forward to his insights contributing to the next phase of our commercial growth as a company, especially the Canadian launch of the Evolve Dry Eye products,” said Doug Janzen, CEO of Aequus.

“Stu will build on a commercial foundation that was largely orchestrated by Ian. Ian has been a core part of this team over the past five years, setting Aequus up for success in his departure. We are going to miss working alongside him and I would like to personally thank him for his commitment and many contributions during his time here.”

Ball’s move back to the UK will strengthen the firm’s rapidly growing strategic relationship with Medicom, Janzen said in a statement. “The entire Aequus team will continue to work closely with Ian as both Medicom and Aequus prepare for the launch of Evolve in North America.”

Medicom has made “significant progress” on the audit required for Evolve in Canada, the firm said in a statement.

Medicom’s CEO Simon Martin said he was “delighted” to welcome Ball to the company, where he will serve as commercial director and sit on its executive committee. Ball will be responsible for leading Asia-Pacific and the Americas, where Medicom is partnered with Aequus.

“Ian has an outstanding record of ‘getting things done’ that he demonstrated throughout his career but especially at Aequus and Novartis,” Martin said.

Aequus said it is working towards the launch and will update shareholders as relevant milestones are achieved.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors